v3.25.2
Overview and Basis of Presentation (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 28, 2023
Mar. 31, 2021
Sep. 30, 2024
May 31, 2024
Oct. 31, 2022
Jun. 30, 2025
Sep. 30, 2024
Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Cash, cash equivalents, and marketable securities           $ 1,300.0    
Development And Regulatory Milestone Payments                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Potential development milestone payments, maximum $ 130.0              
Proceeds from sale of contingent payments           $ 10.0    
2010 Agreement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Milestone payment for achievement of specified ex-U.S. commercial milestone event   $ 25.0            
Contingent Payments and Royalty Rights | Vorasidenib                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Milestone payment for achievement of specified ex-U.S. commercial milestone event       $ 1,000.0        
Gain on sale of contingent payments             $ 889.1  
Proceeds from sale of royalty interests, net       $ 905.0     905.0  
Sale of royalty interests, percentage sold       100.00%        
Royalty percent for sales over $1 billion (as a percent)       12.00%        
Percentage of royalty rights retained       3.00%        
Sale of royalty interests, issuance costs             $ 15.9  
Discontinued Operations, Disposed of by Sale | Vorasidenib                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Milestone payment from gain on sale of oncology business     $ 200.0          
Discontinued Operations, Disposed of by Sale | Agios Oncology Business                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Cash proceeds   1,800.0            
Contingent milestone payment   $ 200.0            
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | TIBSOVO | UNITED STATES                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Contingent royalty payment   5.00%     5.00%      
Gain on sale of contingent payments               $ 127.9
Discontinued Operations, Disposed of by Sale | Agios Oncology Business | Vorasidenib | UNITED STATES                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Contingent royalty payment   15.00%